Compare
Johnson & Johnson vs Eli Lilly & Co vs Pfizer Inc vs Bristol Myers Squibb Co
| Latest fiscal year | Johnson & Johnson JNJ | Eli Lilly & Co LLY | Pfizer Inc PFE | Bristol Myers Squibb Co BMY |
|---|---|---|---|---|
| Year ended | 2025-12-28 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $94.19B | $65.18B | $62.58B | $48.19B |
| Revenue growth (YoY) | +6.0% | +44.7% | -1.6% | -0.2% |
| Gross margin | 67.9% | 83.0% (computed) | 74.3% (computed) | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | 28.5% | 31.7% | 12.4% | 14.6% |
| Net income | $26.80B | $20.64B | $7.77B | $7.05B |
| EPS (Diluted) | $11.03 | $22.95 | $1.36 | $3.46 |
| Operating cash flow | $24.53B | $16.81B | $11.70B | $14.16B |
| Free cash flow | $19.70B | n/a | $9.07B | $12.85B |
| Cash & equivalents | $19.71B | $7.27B | $1.14B | $10.21B |
| Total assets | $199.21B | $112.48B | $208.16B | $90.04B |
| Total liabilities | $117.67B | n/a | $121.39B | $71.53B |
| Shareholders' equity | $81.54B | $26.54B | $86.78B | $18.47B |
| Return on year-end equity | 32.9% | 77.8% | 9.0% | 38.2% |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Johnson & Johnson | Eli Lilly & Co | Pfizer Inc | Bristol Myers Squibb Co |
|---|---|---|---|---|
| Latest | $94.19B Ended 2025-12-28 | $65.18B Ended 2025-12-31 | $62.58B Ended 2025-12-31 | $48.19B Ended 2025-12-31 |
| 1 year earlier | $88.82B Ended 2024-12-29 | $45.04B Ended 2024-12-31 | $63.63B Ended 2024-12-31 | $48.30B Ended 2024-12-31 |
| 2 years earlier | $85.16B Ended 2023-12-31 | $34.12B Ended 2023-12-31 | $59.55B Ended 2023-12-31 | $45.01B Ended 2023-12-31 |
| 3 years earlier | $79.99B Ended 2023-01-01 | $28.54B Ended 2022-12-31 | $101.17B Ended 2022-12-31 | $46.16B Ended 2022-12-31 |
| 4 years earlier | $78.74B Ended 2022-01-02 | $28.32B Ended 2021-12-31 | $81.29B Ended 2021-12-31 | $46.38B Ended 2021-12-31 |